Pediatric catheterization laboratory anticoagulation with bivalirudin

Area of Science:

• Pediatric Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Pediatric physicians face challenges with anticoagulation during procedures, particularly in neonates.
• Bivalirudin is a direct thrombin inhibitor used as an anticoagulant.
• Uncertainty exists regarding its optimal use in pediatric populations.

Purpose of the Study:

• To evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and dosing of bivalirudin in pediatric patients undergoing percutaneous intravascular procedures.
• To determine if adult dosing guidelines are applicable to pediatric populations.
• To assess the predictability of bivalirudin's anticoagulant effect in children.

Main Methods:

• A prospective study enrolled 110 pediatric patients (neonates to older children) undergoing percutaneous intravascular procedures for congenital heart disease.
• Patients received a weight-based dose of bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg/hr infusion).
• Blood samples were collected for PK/PD analysis, and safety was monitored for bleeding and thrombosis events.

Main Results:

• Bivalirudin's PK/PD response in pediatric patients was predictable and similar to adults.
• Weight-normalized clearance was faster in neonates, decreasing with age.
• Bivalirudin concentrations were slightly lower in neonates but increased with age.
• Activating clotting time (ACT) response was consistent with adult studies, showing a reasonable correlation with bivalirudin levels.
• Major bleeding occurred in 1.8% and thrombotic events in 8.2% of patients.

Conclusions:

• Bivalirudin's pharmacokinetic and pharmacodynamic profile in pediatric patients is predictable and mirrors that of adults.
• Current adult dosing regimens for bivalirudin are safe and effective for pediatric intravascular procedures.
• The findings support the use of bivalirudin as a procedural anticoagulant in pediatric cardiology.